ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antiviral Drugs for Influenza Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-18J19008
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Antiviral Drugs for Influenza Market Research Report 2025
BUY CHAPTERS

Global Antiviral Drugs for Influenza Market Research Report 2025

Code: QYRE-Auto-18J19008
Report
February 2025
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
BioCryst Pharmaceuticals
Advacare Pharma
Roche
GlaxoSmithKline PLC
Morningside Pharmaceuticals
Teva Pharmaceuticals
Daiichi Sankyo
Shionogi
WOCKHARDT
Avexima

Antiviral Drugs for Influenza Market Size

The global market for Antiviral Drugs for Influenza was valued at US$ 96 million in the year 2024 and is projected to reach a revised size of US$ 141 million by 2031, growing at a CAGR of 5.7% during the forecast period.

Antiviral Drugs for Influenza Market

Antiviral Drugs for Influenza Market

Antiviral drugs for influenza are medications specifically designed to inhibit the replication of influenza viruses within the body. These drugs help reduce the severity and duration of flu symptoms, lower the risk of complications, and, in some cases, prevent infection. Antiviral drugs for influenza are classified into different categories based on their mechanisms of action, including neuraminidase inhibitors (e.g., oseltamivir, zanamivir, peramivir), polymerase inhibitors (e.g., baloxavir marboxil), and M2 proton channel inhibitors (e.g., amantadine, rimantadine, though these are rarely used due to resistance). They are most effective when taken within 48 hours of symptom onset and are typically available by prescription.
North American market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Antiviral Drugs for Influenza include BioCryst Pharmaceuticals, AdvaCare Pharma, Roche, GlaxoSmithKline, Morningside Pharmaceuticals, Avexima, Teva Pharmaceuticals, Daiichi Sankyo, Shionogi, Wockhardt, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antiviral Drugs for Influenza, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antiviral Drugs for Influenza.
The Antiviral Drugs for Influenza market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antiviral Drugs for Influenza market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antiviral Drugs for Influenza manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Antiviral Drugs for Influenza Market Report

Report Metric Details
Report Name Antiviral Drugs for Influenza Market
Accounted market size in year US$ 96 million
Forecasted market size in 2031 US$ 141 million
CAGR 5.7%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors
Segment by Application
  • Over-the-counter (OTC)
  • Prescription (Rx)
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company BioCryst Pharmaceuticals, AdvaCare Pharma, Roche, GlaxoSmithKline, Morningside Pharmaceuticals, Avexima, Teva Pharmaceuticals, Daiichi Sankyo, Shionogi, Wockhardt
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Antiviral Drugs for Influenza in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Antiviral Drugs for Influenza Market growing?

Ans: The Antiviral Drugs for Influenza Market witnessing a CAGR of 5.7% during the forecast period 2025-2031.

What is the Antiviral Drugs for Influenza Market size in 2031?

Ans: The Antiviral Drugs for Influenza Market size in 2031 will be US$ 141 million.

Who are the main players in the Antiviral Drugs for Influenza Market report?

Ans: The main players in the Antiviral Drugs for Influenza Market are BioCryst Pharmaceuticals, AdvaCare Pharma, Roche, GlaxoSmithKline, Morningside Pharmaceuticals, Avexima, Teva Pharmaceuticals, Daiichi Sankyo, Shionogi, Wockhardt

What are the Application segmentation covered in the Antiviral Drugs for Influenza Market report?

Ans: The Applications covered in the Antiviral Drugs for Influenza Market report are Over-the-counter (OTC), Prescription (Rx)

What are the Type segmentation covered in the Antiviral Drugs for Influenza Market report?

Ans: The Types covered in the Antiviral Drugs for Influenza Market report are Neuraminidase Inhibitors, Polymerase Inhibitors

Recommended Reports

Influenza Treatments

Antiviral Drug Markets

Other Infectious Diseases

1 Antiviral Drugs for Influenza Market Overview
1.1 Product Definition
1.2 Antiviral Drugs for Influenza by Type
1.2.1 Global Antiviral Drugs for Influenza Market Value Comparison by Type (2024 VS 2031)
1.2.2 Neuraminidase Inhibitors
1.2.3 Polymerase Inhibitors
1.3 Antiviral Drugs for Influenza by Application
1.3.1 Global Antiviral Drugs for Influenza Market Value by Application (2024 VS 2031)
1.3.2 Over-the-counter (OTC)
1.3.3 Prescription (Rx)
1.4 Global Antiviral Drugs for Influenza Market Size Estimates and Forecasts
1.4.1 Global Antiviral Drugs for Influenza Revenue 2020-2031
1.4.2 Global Antiviral Drugs for Influenza Sales 2020-2031
1.4.3 Global Antiviral Drugs for Influenza Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Antiviral Drugs for Influenza Market Competition by Manufacturers
2.1 Global Antiviral Drugs for Influenza Sales Market Share by Manufacturers (2020-2025)
2.2 Global Antiviral Drugs for Influenza Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Antiviral Drugs for Influenza Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Antiviral Drugs for Influenza, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antiviral Drugs for Influenza, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antiviral Drugs for Influenza, Product Type & Application
2.7 Global Key Manufacturers of Antiviral Drugs for Influenza, Date of Enter into This Industry
2.8 Global Antiviral Drugs for Influenza Market Competitive Situation and Trends
2.8.1 Global Antiviral Drugs for Influenza Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Antiviral Drugs for Influenza Players Market Share by Revenue
2.8.3 Global Antiviral Drugs for Influenza Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiviral Drugs for Influenza Market Scenario by Region
3.1 Global Antiviral Drugs for Influenza Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Antiviral Drugs for Influenza Sales by Region: 2020-2031
3.2.1 Global Antiviral Drugs for Influenza Sales by Region: 2020-2025
3.2.2 Global Antiviral Drugs for Influenza Sales by Region: 2026-2031
3.3 Global Antiviral Drugs for Influenza Revenue by Region: 2020-2031
3.3.1 Global Antiviral Drugs for Influenza Revenue by Region: 2020-2025
3.3.2 Global Antiviral Drugs for Influenza Revenue by Region: 2026-2031
3.4 North America Antiviral Drugs for Influenza Market Facts & Figures by Country
3.4.1 North America Antiviral Drugs for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Antiviral Drugs for Influenza Sales by Country (2020-2031)
3.4.3 North America Antiviral Drugs for Influenza Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiviral Drugs for Influenza Market Facts & Figures by Country
3.5.1 Europe Antiviral Drugs for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Antiviral Drugs for Influenza Sales by Country (2020-2031)
3.5.3 Europe Antiviral Drugs for Influenza Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiviral Drugs for Influenza Market Facts & Figures by Region
3.6.1 Asia Pacific Antiviral Drugs for Influenza Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Antiviral Drugs for Influenza Sales by Region (2020-2031)
3.6.3 Asia Pacific Antiviral Drugs for Influenza Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiviral Drugs for Influenza Market Facts & Figures by Country
3.7.1 Latin America Antiviral Drugs for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Antiviral Drugs for Influenza Sales by Country (2020-2031)
3.7.3 Latin America Antiviral Drugs for Influenza Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antiviral Drugs for Influenza Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiviral Drugs for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2020-2031)
3.8.3 Middle East and Africa Antiviral Drugs for Influenza Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiviral Drugs for Influenza Sales by Type (2020-2031)
4.1.1 Global Antiviral Drugs for Influenza Sales by Type (2020-2025)
4.1.2 Global Antiviral Drugs for Influenza Sales by Type (2026-2031)
4.1.3 Global Antiviral Drugs for Influenza Sales Market Share by Type (2020-2031)
4.2 Global Antiviral Drugs for Influenza Revenue by Type (2020-2031)
4.2.1 Global Antiviral Drugs for Influenza Revenue by Type (2020-2025)
4.2.2 Global Antiviral Drugs for Influenza Revenue by Type (2026-2031)
4.2.3 Global Antiviral Drugs for Influenza Revenue Market Share by Type (2020-2031)
4.3 Global Antiviral Drugs for Influenza Price by Type (2020-2031)
5 Segment by Application
5.1 Global Antiviral Drugs for Influenza Sales by Application (2020-2031)
5.1.1 Global Antiviral Drugs for Influenza Sales by Application (2020-2025)
5.1.2 Global Antiviral Drugs for Influenza Sales by Application (2026-2031)
5.1.3 Global Antiviral Drugs for Influenza Sales Market Share by Application (2020-2031)
5.2 Global Antiviral Drugs for Influenza Revenue by Application (2020-2031)
5.2.1 Global Antiviral Drugs for Influenza Revenue by Application (2020-2025)
5.2.2 Global Antiviral Drugs for Influenza Revenue by Application (2026-2031)
5.2.3 Global Antiviral Drugs for Influenza Revenue Market Share by Application (2020-2031)
5.3 Global Antiviral Drugs for Influenza Price by Application (2020-2031)
6 Key Companies Profiled
6.1 BioCryst Pharmaceuticals
6.1.1 BioCryst Pharmaceuticals Company Information
6.1.2 BioCryst Pharmaceuticals Description and Business Overview
6.1.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.1.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
6.1.5 BioCryst Pharmaceuticals Recent Developments/Updates
6.2 AdvaCare Pharma
6.2.1 AdvaCare Pharma Company Information
6.2.2 AdvaCare Pharma Description and Business Overview
6.2.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
6.2.5 AdvaCare Pharma Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche Antiviral Drugs for Influenza Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Company Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Morningside Pharmaceuticals
6.5.1 Morningside Pharmaceuticals Company Information
6.5.2 Morningside Pharmaceuticals Description and Business Overview
6.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
6.5.5 Morningside Pharmaceuticals Recent Developments/Updates
6.6 Avexima
6.6.1 Avexima Company Information
6.6.2 Avexima Description and Business Overview
6.6.3 Avexima Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Avexima Antiviral Drugs for Influenza Product Portfolio
6.6.5 Avexima Recent Developments/Updates
6.7 Teva Pharmaceuticals
6.7.1 Teva Pharmaceuticals Company Information
6.7.2 Teva Pharmaceuticals Description and Business Overview
6.7.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
6.7.5 Teva Pharmaceuticals Recent Developments/Updates
6.8 Daiichi Sankyo
6.8.1 Daiichi Sankyo Company Information
6.8.2 Daiichi Sankyo Description and Business Overview
6.8.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
6.8.5 Daiichi Sankyo Recent Developments/Updates
6.9 Shionogi
6.9.1 Shionogi Company Information
6.9.2 Shionogi Description and Business Overview
6.9.3 Shionogi Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
6.9.5 Shionogi Recent Developments/Updates
6.10 Wockhardt
6.10.1 Wockhardt Company Information
6.10.2 Wockhardt Description and Business Overview
6.10.3 Wockhardt Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
6.10.5 Wockhardt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiviral Drugs for Influenza Industry Chain Analysis
7.2 Antiviral Drugs for Influenza Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiviral Drugs for Influenza Production Mode & Process Analysis
7.4 Antiviral Drugs for Influenza Sales and Marketing
7.4.1 Antiviral Drugs for Influenza Sales Channels
7.4.2 Antiviral Drugs for Influenza Distributors
7.5 Antiviral Drugs for Influenza Customer Analysis
8 Antiviral Drugs for Influenza Market Dynamics
8.1 Antiviral Drugs for Influenza Industry Trends
8.2 Antiviral Drugs for Influenza Market Drivers
8.3 Antiviral Drugs for Influenza Market Challenges
8.4 Antiviral Drugs for Influenza Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
BioCryst Pharmaceuticals
Advacare Pharma
Roche
GlaxoSmithKline PLC
Morningside Pharmaceuticals
Teva Pharmaceuticals
Daiichi Sankyo
Shionogi
WOCKHARDT
Avexima
List of Tables
 Table 1. Global Antiviral Drugs for Influenza Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Antiviral Drugs for Influenza Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Antiviral Drugs for Influenza Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Antiviral Drugs for Influenza Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Antiviral Drugs for Influenza Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Antiviral Drugs for Influenza Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Antiviral Drugs for Influenza Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Antiviral Drugs for Influenza Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Antiviral Drugs for Influenza, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Antiviral Drugs for Influenza, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Antiviral Drugs for Influenza, Product Type & Application
 Table 12. Global Key Manufacturers of Antiviral Drugs for Influenza, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Antiviral Drugs for Influenza by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antiviral Drugs for Influenza as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Antiviral Drugs for Influenza Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Antiviral Drugs for Influenza Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Antiviral Drugs for Influenza Sales Market Share by Region (2020-2025)
 Table 19. Global Antiviral Drugs for Influenza Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Antiviral Drugs for Influenza Sales Market Share by Region (2026-2031)
 Table 21. Global Antiviral Drugs for Influenza Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2020-2025)
 Table 23. Global Antiviral Drugs for Influenza Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2026-2031)
 Table 25. North America Antiviral Drugs for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Antiviral Drugs for Influenza Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Antiviral Drugs for Influenza Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Antiviral Drugs for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Antiviral Drugs for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Antiviral Drugs for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Antiviral Drugs for Influenza Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Antiviral Drugs for Influenza Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Antiviral Drugs for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Antiviral Drugs for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Antiviral Drugs for Influenza Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Antiviral Drugs for Influenza Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Antiviral Drugs for Influenza Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Antiviral Drugs for Influenza Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Antiviral Drugs for Influenza Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antiviral Drugs for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Antiviral Drugs for Influenza Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Antiviral Drugs for Influenza Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Antiviral Drugs for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Antiviral Drugs for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Antiviral Drugs for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Antiviral Drugs for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Antiviral Drugs for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Antiviral Drugs for Influenza Sales (K Dose) by Type (2020-2025)
 Table 51. Global Antiviral Drugs for Influenza Sales (K Dose) by Type (2026-2031)
 Table 52. Global Antiviral Drugs for Influenza Sales Market Share by Type (2020-2025)
 Table 53. Global Antiviral Drugs for Influenza Sales Market Share by Type (2026-2031)
 Table 54. Global Antiviral Drugs for Influenza Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Antiviral Drugs for Influenza Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2020-2025)
 Table 57. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2026-2031)
 Table 58. Global Antiviral Drugs for Influenza Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Antiviral Drugs for Influenza Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Antiviral Drugs for Influenza Sales (K Dose) by Application (2020-2025)
 Table 61. Global Antiviral Drugs for Influenza Sales (K Dose) by Application (2026-2031)
 Table 62. Global Antiviral Drugs for Influenza Sales Market Share by Application (2020-2025)
 Table 63. Global Antiviral Drugs for Influenza Sales Market Share by Application (2026-2031)
 Table 64. Global Antiviral Drugs for Influenza Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Antiviral Drugs for Influenza Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2020-2025)
 Table 67. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2026-2031)
 Table 68. Global Antiviral Drugs for Influenza Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Antiviral Drugs for Influenza Price (US$/Dose) by Application (2026-2031)
 Table 70. BioCryst Pharmaceuticals Company Information
 Table 71. BioCryst Pharmaceuticals Description and Business Overview
 Table 72. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product
 Table 74. BioCryst Pharmaceuticals Recent Developments/Updates
 Table 75. AdvaCare Pharma Company Information
 Table 76. AdvaCare Pharma Description and Business Overview
 Table 77. AdvaCare Pharma Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. AdvaCare Pharma Antiviral Drugs for Influenza Product
 Table 79. AdvaCare Pharma Recent Developments/Updates
 Table 80. Roche Company Information
 Table 81. Roche Description and Business Overview
 Table 82. Roche Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. Roche Antiviral Drugs for Influenza Product
 Table 84. Roche Recent Developments/Updates
 Table 85. GlaxoSmithKline Company Information
 Table 86. GlaxoSmithKline Description and Business Overview
 Table 87. GlaxoSmithKline Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. GlaxoSmithKline Antiviral Drugs for Influenza Product
 Table 89. GlaxoSmithKline Recent Developments/Updates
 Table 90. Morningside Pharmaceuticals Company Information
 Table 91. Morningside Pharmaceuticals Description and Business Overview
 Table 92. Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Morningside Pharmaceuticals Antiviral Drugs for Influenza Product
 Table 94. Morningside Pharmaceuticals Recent Developments/Updates
 Table 95. Avexima Company Information
 Table 96. Avexima Description and Business Overview
 Table 97. Avexima Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. Avexima Antiviral Drugs for Influenza Product
 Table 99. Avexima Recent Developments/Updates
 Table 100. Teva Pharmaceuticals Company Information
 Table 101. Teva Pharmaceuticals Description and Business Overview
 Table 102. Teva Pharmaceuticals Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Teva Pharmaceuticals Antiviral Drugs for Influenza Product
 Table 104. Teva Pharmaceuticals Recent Developments/Updates
 Table 105. Daiichi Sankyo Company Information
 Table 106. Daiichi Sankyo Description and Business Overview
 Table 107. Daiichi Sankyo Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Daiichi Sankyo Antiviral Drugs for Influenza Product
 Table 109. Daiichi Sankyo Recent Developments/Updates
 Table 110. Shionogi Company Information
 Table 111. Shionogi Description and Business Overview
 Table 112. Shionogi Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 113. Shionogi Antiviral Drugs for Influenza Product
 Table 114. Shionogi Recent Developments/Updates
 Table 115. Wockhardt Company Information
 Table 116. Wockhardt Description and Business Overview
 Table 117. Wockhardt Antiviral Drugs for Influenza Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 118. Wockhardt Antiviral Drugs for Influenza Product
 Table 119. Wockhardt Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Antiviral Drugs for Influenza Distributors List
 Table 123. Antiviral Drugs for Influenza Customers List
 Table 124. Antiviral Drugs for Influenza Market Trends
 Table 125. Antiviral Drugs for Influenza Market Drivers
 Table 126. Antiviral Drugs for Influenza Market Challenges
 Table 127. Antiviral Drugs for Influenza Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Antiviral Drugs for Influenza
 Figure 2. Global Antiviral Drugs for Influenza Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antiviral Drugs for Influenza Market Share by Type: 2024 & 2031
 Figure 4. Neuraminidase Inhibitors Product Picture
 Figure 5. Polymerase Inhibitors Product Picture
 Figure 6. Global Antiviral Drugs for Influenza Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antiviral Drugs for Influenza Market Share by Application: 2024 & 2031
 Figure 8. Over-the-counter (OTC)
 Figure 9. Prescription (Rx)
 Figure 10. Global Antiviral Drugs for Influenza Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Antiviral Drugs for Influenza Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Antiviral Drugs for Influenza Sales (2020-2031) & (K Dose)
 Figure 13. Global Antiviral Drugs for Influenza Average Price (US$/Dose) & (2020-2031)
 Figure 14. Antiviral Drugs for Influenza Report Years Considered
 Figure 15. Antiviral Drugs for Influenza Sales Share by Manufacturers in 2024
 Figure 16. Global Antiviral Drugs for Influenza Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Antiviral Drugs for Influenza Players: Market Share by Revenue in Antiviral Drugs for Influenza in 2024
 Figure 18. Antiviral Drugs for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Antiviral Drugs for Influenza Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Antiviral Drugs for Influenza Sales Market Share by Country (2020-2031)
 Figure 21. North America Antiviral Drugs for Influenza Revenue Market Share by Country (2020-2031)
 Figure 22. United States Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Antiviral Drugs for Influenza Sales Market Share by Country (2020-2031)
 Figure 25. Europe Antiviral Drugs for Influenza Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Antiviral Drugs for Influenza Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Antiviral Drugs for Influenza Revenue Market Share by Region (2020-2031)
 Figure 33. China Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America Antiviral Drugs for Influenza Sales Market Share by Country (2020-2031)
 Figure 41. Latin America Antiviral Drugs for Influenza Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Colombia Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Antiviral Drugs for Influenza Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Antiviral Drugs for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Antiviral Drugs for Influenza by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Antiviral Drugs for Influenza by Type (2020-2031)
 Figure 53. Global Antiviral Drugs for Influenza Price (US$/Dose) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Antiviral Drugs for Influenza by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Antiviral Drugs for Influenza by Application (2020-2031)
 Figure 56. Global Antiviral Drugs for Influenza Price (US$/Dose) by Application (2020-2031)
 Figure 57. Antiviral Drugs for Influenza Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Influenza Flu Antiviral Drugs Market Insights Forecast to 2030
Antivirals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oseltamivir Market Insights Forecast to 2030
Global Tamiflu Oseltamivir Phosphate Market Insights Forecast to 2030
Global Anti Influenza Virus Chinese Medicine Market Research Report 2024
Zanamivir Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oseltamivir Phosphate API Market Research Report 2025
Influenza Antiviral Drugs Market
Oseltamivir Phosphate Antiviral Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antiviral Drug Packaging Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Paediatric Influenza Treatment Market Research Report 2024
Global Neuraminidase Inhibitor Market Research Report 2024
Neuraminidase Inhibitors Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antiviral Drugs for the Treatment of Hepatitis C HCV Market Research Report 2024
Global Peramivir Market Research Report 2024
Global Ophthalmic Antivirals Market Research Report 2025
Global Influenza Therapeutics Market Insights Forecast to 2030
Global Flu RNA Vaccines Market Research Report 2025
Novel Antiviral Drugs Market
Global Injection Influenza Vaccine Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions